A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer

Objectives Sporadic colorectal cancer (CRC) is considered a multifactorial disease where multiple exposures interact with the individual genetic background resulting in risk modulation. We performed an association study aimed to investigate the role of single nucleotide polymorphisms (SNPs) within genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2D6, CYP2E1, CYP2C9, CYP2C19, CYP3A4, ADH2, EPHX1) and phase II of the xenobiotic metabolism (ALDH2, COMT, GSTA2, GSTA4, GSTM1, GSTM3, GSTP1, GSTT2, MTHFR, NAT1, NAT2, NQO1, MnSOD2, SULT1A1, TPMT). Methods We genotyped 377 cases and 326 controls, by use of an oligonucleotide micro-array and the arrayed primer extension technique (APEX). Results N-acetyl-transferase 1 ‘rapid’ phenotype and CYP1A2 −164C>A carriers were associated with increased risk of CRC, confirming data reported in previous studies. Interestingly, homozygotes for allele 48G within CYP1B1, a variant with an increased activity towards several substrates including sex hormones, were at increased risk (OR=2.81, 95% CI 1.32–5.99). Moreover, CYP1A1 SNPs T461N and −1738A>C were associated with a reduced risk of cancer (OR=0.52; 95% CI 0.31–0.88 and OR=0.69, 95% CI 0.50–0.94 for carriers, respectively). Conclusions The present data suggest a role for CYP1B1 and CYP1A1 as new candidate genes in the etiology of CRC and confirm the carcinogenic role of aromatic amines metabolism for colorectum.

[1]  G. Kearns,et al.  Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. , 1999, Pharmacogenetics.

[2]  X. Shu,et al.  Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  I. de Waziers,et al.  Detection and characterization of novel polymorphisms in the CYP2E1 gene. , 1998, Pharmacogenetics.

[4]  A R Boobis,et al.  CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. , 1994, Cancer research.

[5]  A. Thiel,et al.  Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports. , 1994, Nucleic acids research.

[6]  Federica Gemignani,et al.  Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. , 2003, BioTechniques.

[7]  R. Sinha,et al.  Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. , 2002, Pharmacogenetics.

[8]  A. Metspalu,et al.  DNA resequencing, mutation detection and gene expression analysis by oligonucleotide microchips , 1999 .

[9]  A. Metspalu,et al.  Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology. , 2000, Genetic testing.

[10]  R. Houlston.  CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. , 2000, Pharmacogenetics.

[11]  A. Di Leo,et al.  Estrogens and colorectal cancer. , 2001, Current drug targets. Immune, endocrine and metabolic disorders.

[12]  J. Potter,et al.  Hormone replacement therapy in relation to survival in women diagnosed with colon cancer , 2003, Cancer Causes & Control.

[13]  R. Dahiya,et al.  Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. , 2002, Biochemical and biophysical research communications.

[14]  L. Kolonel,et al.  Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  H. Dienemann,et al.  Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. , 2001, Pharmacogenetics.

[16]  L. Le Marchand,et al.  Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States) , 2003, Cancer Causes & Control.

[17]  M. Ingelman-Sundberg,et al.  Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. , 2001, Biochemical and biophysical research communications.

[18]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[19]  D. Bell,et al.  Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. , 1995, Cancer research.

[20]  Stefano Landi,et al.  Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. , 2003, Cancer research.

[21]  L. Kolonel,et al.  Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  A. Sajantila,et al.  Y-chromosomal SNPs in Finno-Ugric-speaking populations analyzed by minisequencing on microarrays. , 2001, Genome research.

[23]  M. Hewison,et al.  Estrogen metabolism and malignancy: analysis of the expression and function of 17β-hydroxysteroid dehydrogenases in colonic cancer , 2001, Molecular and Cellular Endocrinology.

[24]  M. Watson,et al.  Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. , 2001, Carcinogenesis.

[25]  Giovanni Romeo,et al.  Reliable Detection of β-Thalassemia and G6PD Mutations by a DNA Microarray , 2002 .

[26]  P. Vineis,et al.  Metabolic gene polymorphism frequencies in control populations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  R. Houlston,et al.  Polymorphisms and colorectal tumor risk. , 2001, Gastroenterology.

[28]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[29]  N. Roodi,et al.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. , 2000, Cancer research.

[30]  Andres Metspalu,et al.  Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  I. Roots,et al.  Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. , 2001, Carcinogenesis.

[33]  Q. Ma,et al.  Induction of CYP1A1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding biological roles. , 2001, Current drug metabolism.

[34]  D. Labuda,et al.  Genetic Susceptibility to Childhood Acute Lymphoblastic Leukemia , 2000, Leukemia & lymphoma.

[35]  P. Beaune,et al.  Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. , 1996, Pharmacogenetics.

[36]  A. Conney,et al.  Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. , 1982, Cancer research.

[37]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[38]  E. D. de Vries,et al.  Low-penetrance genes and their involvement in colorectal cancer susceptibility. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[40]  F. Canzian,et al.  A catalogue of polymorphisms related to xenobiotic metabolism and cancer susceptibility. , 2002, Pharmacogenetics (London).

[41]  J. Lafitte,et al.  Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. , 1997, Pharmacogenetics.

[42]  J. Barrett,et al.  A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. , 2002, Carcinogenesis.